Structure’s stock jump Friday — shares were up by more than 40% at one point — reflects investor enthusiasm for GLP-1 drugs, which promise to upend how obesity is treated.
Already, demand for Novo Nordisk’s Ozempic and Wegovy as well as Eli Lilly’s competing Mounjaro has outstripped the ability of those companies to make sufficient supplies, leading to shortages. The drugs’ fast sales has in turn sparked a pharmaceutical industry gold rush to develop newer versions, in which Structure is a rising player.
